Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101764987 | 10176498 | 7 | F | 20140111 | 20160808 | 20140516 | 20160818 | EXP | US-PFIZER INC-2014125475 | PFIZER | 16.00 | YR | F | Y | 72.30000 | KG | 20160818 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101764987 | 10176498 | 1 | PS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | COURSE A: 165 MG/M2, (250MG) 2X/DAY ON DAYS 1-21 | Y | 202570 | 250 | MG | BID | ||||||
| 101764987 | 10176498 | 2 | SS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | UNK | Y | 202570 | |||||||||
| 101764987 | 10176498 | 3 | SS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | LOWER DOSE PER PROTOCOL (DOSE GROUP C) | Y | 202570 | |||||||||
| 101764987 | 10176498 | 4 | SS | HYDROCORTISONE ACETATE. | HYDROCORTISONE ACETATE | 1 | Intrathecal | PROPHASE (CYCLE= 5 DAYS): 7.5-12 MG ON DAY 1 (AGE BASED DOSING) | 8917 | ||||||||||
| 101764987 | 10176498 | 5 | SS | CYTARABINE. | CYTARABINE | 1 | Intrathecal | PROPHASE (CYCLE= 5 DAYS): 15-24 MG ON DAY 1 (AGE BASED DOSING), (24 MG) | 71868 | 24 | MG | ||||||||
| 101764987 | 10176498 | 6 | SS | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | COURSE A: 150MG/M2 IV OVER 1-30 MINUTES Q12 HOURS ON DAYS 4 AND 5 | 71868 | 150 | MG/M**2 | ||||||||
| 101764987 | 10176498 | 7 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intrathecal | PROPHASE (CYCLE= 5 DAYS): 7.5-12 MG ON DAY 1 (AGE BASED DOSING) | 11719 | ||||||||||
| 101764987 | 10176498 | 8 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | COURSE A: 3000 MG/M2, IV OVER 3 HOURS ON DAY 1 | 11719 | 3000 | MG/M**2 | ||||||||
| 101764987 | 10176498 | 9 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | COURSE A: 100 MG/M2, OVER 2 HOURS ON DAYS 4 AND 5 | 0 | 100 | MG/M**2 | ||||||||
| 101764987 | 10176498 | 10 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | PROPHASE (CYCLE= 5 DAYS): 5MG/M2 1X/DAY ON DAYS 1-2 AND 5MG/M2 PO BID ON DAYS 3-5, (72 MG) | 0 | 72 | MG | ||||||||
| 101764987 | 10176498 | 11 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | COURSE A: 5 MG/M2, 2X/DAY ON DAYS 1-5 | 0 | 90 | MG | ||||||||
| 101764987 | 10176498 | 12 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | COURSE A: 800 MG/M2, IV OVER 60 MINUTES ON DAYS 1-5 | 0 | 800 | MG/M**2 | ||||||||
| 101764987 | 10176498 | 13 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | PROPHASE (CYCLE= 5 DAYS): 200 MG/M2, IV OVER 30-60 MIN ON DAYS 1 AND 2 | 0 | 200 | MG/M**2 | ||||||||
| 101764987 | 10176498 | 14 | C | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 101764987 | 10176498 | 15 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 101764987 | 10176498 | 1 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 4 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 5 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 7 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 9 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 10 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 12 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 13 | Anaplastic large cell lymphoma T- and null-cell types |
| 101764987 | 10176498 | 14 | Nausea |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 101764987 | 10176498 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 101764987 | 10176498 | Colitis | |
| 101764987 | 10176498 | Ileus | |
| 101764987 | 10176498 | Posterior reversible encephalopathy syndrome | |
| 101764987 | 10176498 | Seizure | |
| 101764987 | 10176498 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 101764987 | 10176498 | 1 | 20140111 | 20140111 | 0 | |
| 101764987 | 10176498 | 2 | 20140112 | 201401 | 0 | |
| 101764987 | 10176498 | 3 | 20140122 | 20140124 | 0 | |
| 101764987 | 10176498 | 4 | 20140106 | 20140106 | 0 | |
| 101764987 | 10176498 | 5 | 20140106 | 20140106 | 0 | |
| 101764987 | 10176498 | 6 | 20140114 | 0 | ||
| 101764987 | 10176498 | 7 | 20140106 | 20140106 | 0 | |
| 101764987 | 10176498 | 8 | 20140111 | 0 | ||
| 101764987 | 10176498 | 9 | 20140114 | 0 | ||
| 101764987 | 10176498 | 10 | 20140106 | 20140110 | 0 | |
| 101764987 | 10176498 | 11 | 20140111 | 0 | ||
| 101764987 | 10176498 | 12 | 20140111 | 0 | ||
| 101764987 | 10176498 | 13 | 20140106 | 20140107 | 0 | |
| 101764987 | 10176498 | 15 | 20140111 | 0 |